

## Technology Advisory Committee B Interests Register

### Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma [ID4057]

Publication Date: 06/06/2023

| Name  | Role with NICE  | Type of interest                   | Description of interest   | Interest arose | Interest declared | Interest ceased | Comments  |
|---|-----------------|------------------------------------|---|----------------|-------------------|-----------------|---|
| Neil Rabin,<br>Consultant<br>Haematologist  | Clinical Expert | Indirect<br>Financial              | Neil declared he has received honoraria from several companies including Janssen.   | N/A            | 08/02/23          | N/A             | It was agreed that his declaration would not prevent Neil Rabin from providing expert advice to the committee       |
| Shelagh<br>McKinley, Acting<br>Director of<br>Research and<br>Advocacy / Head<br>of Patient<br>Advocacy | Clinical Expert | Indirect<br>Financial              | Shelagh declared her organisation Myleoma UK have received grant funding and occasional honoraria from submitting company as well companies that are comparators in this appraisal. | N/A            | 08/02/23          | N/A             | It was agreed that his declaration would not prevent Shelagh McKinley from providing expert advice to the committee |
| Peter Wheatley<br>Price,<br>Pharmaceutical<br>Industry  | TAC B<br>member | Direct -<br>Financial<br>Intererst | Peter declared that as Takeda manufacture ixazomib which is used in combination with lenalidomide and dexamethasone for treating relapsed or refractory multiple myleoma (TA505).   | N/A            | 26/01/23          | N/A             | It was agreed that his declaration would prevent Peter Wheatley Price from providing expert advice.                 |

| Name                                   | Role with NICE  | Type of interest                    | Description of interest  | Interest arose | Interest declared | Interest ceased | Comments  |
|--|-----------------|-------------------------------------|--|----------------|-------------------|-----------------|---|
|  |                 |                                     | We have just successfully exited the CDF (ID1635).   |                |                   |                 |   |
| Dr. Warren Linley,<br>Health Economist | TAC B<br>Member | Indirect -<br>Financial<br>interest | Warren declared that Amgen is listed as the manufacturer of a potential comparator for the appraisal of daratumumab with bortezomib and dexamethasone [ID4057]. And he hold shares in Amgen that I was granted as a previous employee. | N/A            | 19/01/23          | N/A             | It was agreed that his declaration would prevent Warren Linley, Price from providing expert advice. |